Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | PREP | P48147 | 4/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.38 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2690291 | 1.00 | CHRM2 (0.44) | CHRM2CHRM1CHRM3PREPRECQL | |
| SCHEMBL2690295 | 1.00 | CHRM2 (0.44) | CHRM2CHRM1CHRM3PREPRECQL | |
| SCHEMBL7194471 | 1.00 | CHRM2 (0.44) | CHRM2CHRM1CHRM3PREPRECQL | |
| SCHEMBL2909390 | 0.85 | CHRM2 (0.53) | CHRM2CHRM1CHRM3PREPRECQL | |
| SCHEMBL19570649 | 0.79 | CHRM2 (0.55) | CHRM2CHRM1CHRM3PREPRECQL | |
| SCHEMBL3091698 | 0.79 | CHRM2 (0.55) | CHRM2CHRM1CHRM3PREPRECQL | |
| SCHEMBL9819883 | 0.79 | PREP (0.44) | CHRM2CHRM1CHRM3PREPEPHX1 | |
| SCHEMBL4308752 | 0.78 | CHRM2 (0.51) | CHRM2CHRM1CHRM3PREPEPHX1 | |
| SCHEMBL4299549 | 0.78 | CHRM2 (0.51) | CHRM2CHRM1CHRM3PREPEPHX1 | |
| SCHEMBL31046592 | 0.78 | CHRM2 (0.44) | CHRM2CHRM1CHRM3PREPEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168657-B2 | administering a solenopsin derivative such as 2-methyl-6-(2-phenylethyl)piperidine or other piperidine derivatives to treat a tumor or cancer in a patient | BOWEN J PHILLIP (US) | 2012-05-01 | — | — | US | disclosed |
| US-20050038071-A1 | Solenopsin a, b and analogs and as novel angiogenesis inhibitors | BOWEN J PHILLIP (US) | 2005-02-17 | — | — | US | disclosed |
| US-6369078-B1 | Solenopsin derivatives and analogues as fire ant suppressants | BOWEN J PHILLIP (US) | 2002-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038071-A1 | Solenopsin a, b and analogs and as novel angiogenesis inhibitors | VEGFA, TEK, FLT1 | CHRM2 4884/4885CHRM1 4872/4885CHRM3 4885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.